Peptide record

TPDB91443

Temporin-SHf Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity modified_plain modified
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91443
Temporin-SHf
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP CAFPdb dbAMP 3.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 8-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FFFLSRIF-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
8 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Pelophylax saharica Activity
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 24.03 ± 0.945 µM
Anticancer
24.03

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2024

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

IC50
IC50 = 32.76 ± 1.528 µM
Anticancer
32.76

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2024
Evidence 3 Activity

Activity

IC50
IC50 = 36.67 ± 0.729 µM
Anticancer
36.67

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2024
Evidence 4 Activity

Activity

IC50
IC50 = 32.64 ± 1.350 µM
Anticancer
32.64

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2024